Restructuring, Impairment and Related Costs (Tables)

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

The following table is a summary of restructuring charges incurred under both the 2023 and 2024 Restructuring Plans and a roll forward of accrued restructuring costs (in thousands). The actions related to 2023 Restructuring Plan and 2024 Restructuring Plan were substantially completed by the end of 2024.


	Severance and other employee-related expenses		Long-lived assets impairment and disposal losses		Lease termination gain		Total
Accrued restructuring charges at December 31, 2022	$	—	$	—	$	—	$	—
Restructuring charges, net	5,898		7,661(1)		—		13,559
Cash payment	(1,444)		—		—		(1,444)
Non-cash activity	—		(7,661)		—		(7,661)
Accrued restructuring charges at December 31, 2023	$	4,454	$	—	$	—	$	4,454
Restructuring charges, net	10,822		26,499(2)		(2,326)(3)		34,995
Cash payment	(13,664)		—		—		(13,664)
Non-cash activity	—		(26,499)		2,326		(24,173)
Accrued restructuring charges at December 31, 2024	$	1,612	$	—	$	—	$	1,612

(1) Disclosed amount primarily consists of $5.4 million impairment charges recorded upon the Company ceasing to use the leased space at 499 Illinois Street, San Francisco, California, former corporate headquarter in 2023. The related ROU assets and leasehold improvements were evaluated for impairment as a separate asset group, the carrying value of which was determined to be not recoverable. $4.2 million impairment related to the ROU assets and $1.2 million impairment related the leasehold improvements were recognized to reduce the carrying value to an estimated fair value of zero.

(2) Disclosed amount primarily consists of $25.3 million impairment charges recorded due to the closure of the R&D facilities in St. Louis, Missouri and Portland, Oregon in 2024. The related ROU assets and leasehold improvements were evaluated for impairment as two separate asset groups and determined to be abandoned upon the closure of the R&D facilities. $20.3 million impairment related to the leasehold improvements and $5.0 million related to the ROU assets were recognized to write off the carrying value. The lease agreement related to the R&D facility in St. Louis, Missouri was terminated in December 2024.

(3) Disclosed amount relates to the $2.3 million gain from the de-recognition of lease liability upon the termination of the lease agreement related to the R&D facility in St. Louis, Missouri in December 2024.